Zheng Quan Shi Bao Wang·2025-12-15 12:25Core Viewpoint - Shanghai Pharmaceuticals has received approval for its innovative drug, Suojirolin, aimed at treating primary hypertension, marking a significant achievement in its commitment to independent innovation in the pharmaceutical industry [1][2]. Group 1: Product Approval and Clinical Significance - The National Medical Products Administration (NMPA) has officially approved Suojirolin (brand name: Xintuoan), a first-class innovative drug for the treatment of primary hypertension [1]. - Suojirolin is a new generation of oral non-peptide small molecule renin inhibitors, designed to meet unmet clinical needs, providing a new treatment option for over 300 million patients with primary hypertension in China [1]. - Clinical trials have shown that Suojirolin demonstrates good efficacy and safety, with its Phase II trial results published in the authoritative journal "Hypertension Research," indicating growing global academic interest in Chinese innovative drugs [1]. Group 2: Research and Development Strategy - Shanghai Pharmaceuticals has positioned research and development (R&D) innovation at its strategic core, with a planned R&D investment of 2.818 billion yuan for 2024, leading the industry in investment intensity [2]. - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, including 45 innovative drug pipelines, establishing a comprehensive and tiered R&D team [2]. - The company has several innovative drugs in advanced clinical stages, including a CD20 injection for neuromyelitis optica and a traditional Chinese medicine for cervical spondylosis, indicating a robust pipeline [2]. Group 3: Collaborative Innovation and Market Strategy - Shanghai Pharmaceuticals has established the Shanghai Frontier Biomedical Innovation Center to foster an open innovation ecosystem by collaborating with top universities and research institutions [3]. - The company has created a comprehensive distribution network covering over 80,000 medical institutions across 25 provinces and municipalities in China, ensuring effective market access for Suojirolin [3]. - The integration of online and offline pharmaceutical services enhances the company's ability to reach patients quickly and efficiently [3].